PMID- 35646399
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20240201
IS  - 2090-2840 (Print)
IS  - 2090-2859 (Electronic)
IS  - 2090-2840 (Linking)
VI  - 2022
DP  - 2022
TI  - Clinical Comparative Study of Intravitreal Injection of Triamcinolone Acetonide 
      and Aflibercept in the Treatment of Diabetic Retinopathy Cystoid Macular Edema.
PG  - 1348855
LID - 10.1155/2022/1348855 [doi]
LID - 1348855
AB  - Objective To compare the curative effect of intravitreal injection of 
      triamcinolone acetonide and aflibercept on diabetic retinopathy (DR) cystoid 
      macular edema. Methods A total of 102 patients with DR cystoid macular edema 
      admitted to the hospital were enrolled between July 2018 and July 2021. According 
      to random number table method, they were divided into the control group 
      (intravitreal injection of triamcinolone acetonide) and the observation group 
      (intravitreal injection of aflibercept), 51 cases in each group. All were 
      followed up for half a year. The clinical curative effect, visual acuity, central 
      subfield macular thickness (CSMT), macular volume, scores of quality of life, and 
      levels of cytokines in aqueous humor (vascular endothelial growth factor (VEGF), 
      monocyte chemoattractant protein-1 (MCP-1), human angiopoietin-like protein 4 
      (ANGPTL4)] at different time points (before and at 6 months after surgery) were 
      compared between the two groups. The times of drugs injection and occurrence of 
      adverse reactions in both groups were statistically analyzed. Results The total 
      effective rate in observation group was higher than that in the control group 
      (96.08% vs 82.35%) (P < 0.05). After 6 months of treatment, visual acuity was 
      improved, and CSMT and macular volume were decreased in both groups. Also, the 
      above changes were more significant in the observation group than those in the 
      control group (P < 0.05). After 6 months of treatment, levels of cytokines in 
      aqueous humor were decreased in both groups. The levels of VEGF, MCP-1, and 
      ANGPTL4 in observation group were lower than those in the control group (P < 
      0.05). After 6 months of treatment, quality of life scores in observation group 
      were higher than those in the control group (P < 0.05). In the follow-up period, 
      average times of drugs injection in the observation group were more than those in 
      the control group, and the incidence of adverse reactions was lower than that in 
      control group (5.88% vs 21.57%) (P < 0.05). Conclusion The curative effect of 
      intravitreal injection of both triamcinolone acetonide and aflibercept is good on 
      DR cystoid macular edema. The curative effect of aflibercept is better, which can 
      improve visual acuity and quality of life, and regulate cytokines in aqueous 
      humor, with high safety. However, aflibercept has a high price, and further 
      research is needed to determine whether its price can be matched with clinical 
      benefits. In clinic, medication plan should be selected according to the actual 
      situation.
CI  - Copyright (c) 2022 Yanxia Zhu et al.
FAU - Zhu, Yanxia
AU  - Zhu Y
AD  - Department of Ophthalmology, Lishui Municipal Central Hospital, Lishui, Zhejiang 
      323000, China.
FAU - Li, Jun
AU  - Li J
AD  - Department of Ophthalmology, Lishui Municipal Central Hospital, Lishui, Zhejiang 
      323000, China.
FAU - Yu, Songping
AU  - Yu S
AD  - Department of Ophthalmology, Lishui Municipal Central Hospital, Lishui, Zhejiang 
      323000, China.
FAU - Mao, Bangxun
AU  - Mao B
AD  - Department of Ophthalmology, Lishui Municipal Central Hospital, Lishui, Zhejiang 
      323000, China.
FAU - Ying, Jia
AU  - Ying J
AUID- ORCID: 0000-0002-3333-5849
AD  - Department of Ophthalmology, Lishui Municipal Central Hospital, Lishui, Zhejiang 
      323000, China.
LA  - eng
PT  - Journal Article
PT  - Retracted Publication
DEP - 20220518
PL  - Egypt
TA  - Emerg Med Int
JT  - Emergency medicine international
JID - 101567070
RIN - Emerg Med Int. 2024 Jan 24;2024:9787343. PMID: 38298974
PMC - PMC9132663
COIS- The authors declare that they do not have any commercial or associative interests 
      that represent any conflicts of interest in connection with the work submitted.
EDAT- 2022/06/02 06:00
MHDA- 2022/06/02 06:01
PMCR- 2022/05/18
CRDT- 2022/06/01 11:36
PHST- 2022/03/22 00:00 [received]
PHST- 2022/04/26 00:00 [accepted]
PHST- 2022/06/01 11:36 [entrez]
PHST- 2022/06/02 06:00 [pubmed]
PHST- 2022/06/02 06:01 [medline]
PHST- 2022/05/18 00:00 [pmc-release]
AID - 10.1155/2022/1348855 [doi]
PST - epublish
SO  - Emerg Med Int. 2022 May 18;2022:1348855. doi: 10.1155/2022/1348855. eCollection 
      2022.